ALK Rearrangement in Non–Small Cell Lung Cancer: A Predictive Biomarker Worth Getting Right

Every so often a molecular result reorganizes the entire treatment conversation, and an ALK-rearranged lung adenocarcinoma is one of those moments. When the report comes back positive, a patient who might otherwise have faced conventional chemotherapy becomes a candidate for a class of oral targeted drugs with response rates and durability that chemotherapy simply doesn't match. That's why ALK testing sits at the front of the diagnostic workup for advanced non–squamous NSCLC, and increasingly for earlier-stage disease as well. Here's what the assay measures, how we test for it, and what each result actually determines.

What the Test Measures

ALK (anaplastic lymphoma kinase) is a receptor tyrosine kinase gene on chromosome 2. In a subset of NSCLC — most often adenocarcinomas, frequently in younger patients and never- or light-smokers — a chromosomal rearrangement fuses ALK to a partner gene, most commonly EML4. The fusion places the ALK kinase domain under the control of an active promoter, producing a chimeric protein that signals constitutively and drives tumor proliferation. That aberrant kinase is precisely the target ALK inhibitors are built to block.

The key conceptual point is that ALK is a predictive biomarker, not a prognostic one. We aren't testing to estimate how the disease will behave on its own; we're testing to predict whether a specific drug class is likely to work. Keep that distinction in mind — it shapes how the result is used downstream.

How It's Tested

Three assay types are in routine use, and in practice they work best as a coordinated system rather than as competitors.

Immunohistochemistry (IHC) detects the overexpressed fusion protein and serves as a sensitive, fast, inexpensive screen. On formalin-fixed, paraffin-embedded (FFPE) tissue, a strongly positive IHC stain is a reliable flag. But IHC detects protein, not the genetic event itself, so a positive screen conventionally warrants molecular confirmation before it drives therapy.

Fluorescence in situ hybridization (FISH) uses break-apart probes to detect the rearrangement at the DNA level. It's been a longstanding reference method and directly demonstrates the structural event, though it doesn't identify the fusion partner and can be technically demanding to interpret at the split-signal level.

Next-generation sequencing (NGS) has become the workhorse where it's available. NGS can identify the fusion, name the partner, and — critically — do so alongside the other actionable alterations that guideline-concordant lung workups require, all from a single specimen. RNA-based NGS panels are particularly good at capturing fusions that DNA-based assays can miss.

On specimen and preanalytics: FFPE tissue remains the primary substrate, and tissue quality matters more than people sometimes appreciate. Prolonged or inadequate fixation degrades both antigen and nucleic acid, and a scant or necrotic biopsy can generate a false-negative that no downstream chemistry will rescue. When tissue is insufficient or a repeat biopsy isn't feasible, plasma circulating tumor DNA (ctDNA) offers a "liquid biopsy" alternative. Worth emphasizing here: a positive ctDNA result is actionable, but a negative one isn't reassuring on its own, because tumors that shed little DNA into the blood can read as false-negative. A negative liquid result should push you back toward tissue, not close the question.

Scoring reduces to a binary: fusion present versus absent. IHC functions as the sensitive screen, with FISH or NGS providing the molecular confirmation that anchors the final call.

What Each Result State Means

ALK fusion present. The tumor harbors an ALK rearrangement and is biologically dependent on ALK signaling. This is the result that opens the targeted-therapy pathway.

ALK fusion absent. No rearrangement is detected. The patient isn't a candidate for ALK-directed therapy on the basis of this test, and attention turns to the other biomarkers on the panel. Remember the preanalytic caveat — "absent" is only as trustworthy as the specimen and assay that produced it.

What It Determines for Treatment Eligibility

An ALK fusion–present result informs eligibility for the ALK tyrosine kinase inhibitor (TKI) class. That's the whole point of running the test. In advanced disease, ALK TKIs are the reason to identify these patients in the first place. And the reach now extends earlier: the FDA has approved alectinib, an ALK TKI, as adjuvant treatment following resection in early-stage ALK-positive NSCLC [2]. So a positive result carries weight not only in metastatic disease but in the curative-intent setting after surgery.

To be clear about the framing — a positive result establishes eligibility for this drug class; it doesn't dictate that any individual should receive a particular agent. That decision belongs to the treating oncologist weighing stage, performance status, and the full clinical picture. The regulatory scaffolding here rests on the companion-diagnostic framework, in which specific assays are validated alongside the drugs whose use they gate, supported by the ALK TKI trial data [1][2].

Caveats and What's Evolving

A few things I'd flag from daily practice:

• IHC-positive, molecular-negative discordance happens. These cases need judgment, not reflex. Weak or equivocal IHC staining is exactly where confirmatory FISH or NGS earns its keep, and where a rushed positive call can send someone down the wrong pathway.

• ctDNA is a rule-in, not a rule-out, tool. A negative plasma result in a patient with a compelling clinical phenotype — young, never-smoker, adenocarcinoma — shouldn't end the search. Low tumor shed is a real and underrecognized cause of false-negatives, and tissue remains the arbiter.

• Assay choice affects fusion detection. DNA-only NGS panels can miss certain fusions that RNA-based approaches or FISH will catch. Knowing what your lab's platform does and doesn't cover isn't a technicality — it's the difference between finding the alteration and missing it.

• The landscape keeps moving. New ALK partners, resistance mutations that emerge on therapy, and evolving companion-diagnostic pairings mean today's testing algorithm isn't necessarily next year's [1]. The evidence base here is genuinely fast-moving, and reasonable labs differ on the details of their reflex workflows.

If there's one thing to carry out of this discussion, it's this: an ALK result is only as good as the tissue and the assay behind it. Get a clean answer on a good specimen, confirm your screen, and don't let a negative liquid biopsy talk you out of a diagnosis the clinical picture is practically shouting at you.

References

1. Review. Lung Cancer: Targeted Therapy in 2025. Curr Oncol. 2025. PMC11941068 (verify).
2. U.S. Food & Drug Administration. FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer. Drugs@FDA, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer